Craig A. Tooman

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
London, United Kingdom
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Rhonda Hellums, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Craig A. Tooman

Form 4 holding President and CEO, Director

Silence Therapeutics plc

Security class
Employee Share Option (Right to Buy)
Shares / value
900,000
Estimated value
Report date
02 Jan 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding President and CEO, Director

Silence Therapeutics plc

Security class
Ordinary Shares
Shares / value
33,486
Estimated value
Report date
02 Jan 2025
Price
Ownership
Direct

Insider Reports Filed by Craig A. Tooman

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .